• Phoenix Rising needs funds to operate: please consider donating to support PR

Peptide T for XMRV

M

Mark Lloyd-Fox

Guest
My name is Mark Lloyd-Fox. I am VP of Global Partnerships and Coalitions at RAPID Pharmaceuticals, AG, which is developing monomeric DAPTA (an active 3rd generation proprietary formulation of Peptide T) for HIV disease. The recent discovery that XMRV is the causative agent of CFS provides a scientific rational for the fact that government studies many years ago found profound neurocognitive improvements in CFS patients, because this virus is related to HIV. RAPID is now studying whether monomeric DAPTA can successfully block the XMRV virus in the same way that it works in HIV in the test tube. RAPID is interested in organising FDA approved, controlled clinical trials of monomeric DAPTA for CFS as soon as a clear mechanism of action has been demonstrated and funding for this use has been secured. Some past clinical trials of Peptide T failed because it cannot be made into a durable formulation (beware of internet offers to purchase Peptide T- only monomeric DAPTA has proven bioactivity by a patented technology developed by Drs. Pert and Ruff for RAPID which they helped found). I travel throughout the US and Europe for RAPID and would be delighted to meet any interested parties who feel that they can contribute to the scientific study.
 

aquariusgirl

Senior Member
Messages
1,647
Likes
615
volunteers for clinical trials?

[ I travel throughout the US and Europe for RAPID and would be delighted to meet any interested parties who feel that they can contribute to the scientific study.[/QUOTE]

Hi Mark
Are you saying you would like to recruit CFS patients for possible future clincial trials using your version of Peptide T?

Thanks for clarifying.

AQ
 
M

Mark Lloyd-Fox

Guest
Yes AQ, that would be part of it. We are essentially peptide specialists with all of our scientific and financial resources vested in our HIV therapy. We have other drug candidates for other conditions using the same technology and CFS is a primary next step for RAPID. We are currently researching possibilities within the world of CFS for suitable scientific specialists and funding partners so that we can gear up to effectively address CFS using this remarkable peptide.
MLF.
PS. I am also Aquarius. Thanks for your interest. I am new to this form of communication but will do my best to keep this site informed of developments.
 
M

Mark Lloyd-Fox

Guest
I just thought that I should be perfectly clear that RAPID is NOT recruiting patient volunteers or even taking names until more pre-clinical data has been done and funding is in place.
 

Rrrr

Senior Member
Messages
1,564
Likes
704
Hi Mark,

Given your last statement, that RAPID is not recruiting patient volunteers at this time, please let us know how we can help you or what you are offering or suggesting. I would like to do whatever I can to assist RAPID in the process of developing drugs to treat xmrv and in conducting drug trials. Do you have a phone number we can reach you at, or an email? And can you clarify what it is you are offering/suggesting here?

Thank you for all the work you have done to date! Candace Pert is one dedicated woman, and I assume her staff is as well. So thank you.

Rrrr
 

julius

Watchoo lookin' at?
Messages
785
Likes
5
Location
Canada
Thanks Mark for keeping us informed. I hope your work results in safe and effective new treatments for CFS.
 

Rrrr

Senior Member
Messages
1,564
Likes
704
Mark,

First, I assume you are in touch with Dr. Judy Mikovits at Whittmore Peterson Institute. They expressed an interest in doing a trial with Peptide T re: XMRV.

Separately, might you be looking for Infectious Disease (ID) doctors who can work with RAPID? I will soon be the patient of an ID doctor at very reputable and well known hospital, Dr. Donna Felsenstein of Mass General Hospital. She is currently conducting an XMRV study. I am not sure who funded it. But perhaps she can be interested in working with RAPID on a study re: DAPT. I have yet to meet her, but perhaps you may want to reach out to her.

Rrrr
 

julius

Watchoo lookin' at?
Messages
785
Likes
5
Location
Canada
Rrr,

Check out post #8 on this thread. I transcribed a small part of the talk that Dr Mikovits gave in which she mentioned Peptide T. It was, in fact, Dr Pert who contacted Judy regarding PT. I believe they are already co-operating on this.
 

Rrrr

Senior Member
Messages
1,564
Likes
704
Rrr,

Check out post #8 on this thread. I transcribed a small part of the talk that Dr Mikovits gave in which she mentioned Peptide T. It was, in fact, Dr Pert who contacted Judy regarding PT. I believe they are already co-operating on this.
Thanks. How the heck did I miss that earlier? Thanks again!
 

Forebearance

Senior Member
Messages
565
Likes
378
Location
Great Plains, US
Dear Mark,

Thank you so much for posting on this forum and telling us what is going on within RAPID. I really hope that you get your pre-trial data and your funding in place soon! I can't wait to find out what happens in the clinical trials of monomeric DAPTA on CFS patients. Thank you for wanting to help us!

Forebearance
 

Rrrr

Senior Member
Messages
1,564
Likes
704
i was in touch with RAPID recently and they are very interested in xmrv. that is all i know for sure.
 

xrayspex

Senior Member
Messages
1,097
Likes
388
Location
u.s.a.
peptides

Hey I am reading a book by Candace Pert right now and am reintrigued about peptide t and her studies. reminds me of burzinsky, but she has more obvious credibility with NIH background.

anyone hear anything about this peptide or other ones avail?
 
Messages
1
Likes
0
Peptide T has no antiviral activity, either against HIV or XMRV. Its purported antiviral activity was never confirmed by other scientists, and so it is not being developed as a drug.